Charles Schwab Investment Management Inc Apellis Pharmaceuticals, Inc. Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 989,143 shares of APLS stock, worth $22.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
989,143
Previous 964,499
2.56%
Holding current value
$22.9 Million
Previous $21.1 Million
18.83%
% of portfolio
0.0%
Previous 0.0%
Shares
32 transactions
Others Institutions Holding APLS
# of Institutions
295Shares Held
132MCall Options Held
2.97MPut Options Held
623K-
Avoro Capital Advisors LLC New York, NY12.2MShares$282 Million3.86% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$275 Million17.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$235 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.75MShares$225 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.98MShares$207 Million0.03% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.54B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...